Metabolon secures two new investors, closes on $6 million in financing
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
RESEARCH TRIANGLE PARK, N.C. - Metabolon, a startup focused on biomarker and metabolomics research, has closed on $6 million in new venture funding.
The total raised for the firm’s Series C round is $12.3 million.
New investors include Syngenta Ventures, the venture arm of crop science firm Syngenta, as well as Fletcher Spaght Ventures. Existing investors Aurora Funds, which is based in Durham, along with Sevin Rosen Funds, Harris and Harris Group, Fulcrum Financial Partners and Alexandria Equities also participated.
Metabolon is advancing metabolomics, which is an approach to identifying biomarkers. The firm believes its technology will "dramatically impact drug discovery and development processes."
Carol Marino of Syngenta Ventures and Guy Fish of Fletcher Spaght join Metabolon’s board as part of the investment.
The firm raised $15 million in two earlier rounds of funding after launching in 2000.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
The Skinny
- Epic Games' Tim Sweeney reaps arts Hall of Fame honor today
- Charlotte's startup efforts pick up steam as more data pours in
- 'Battle in Bay 7' returns - Are you techies ready for some basketball?
- Inside RTP's new angel fund: Founders meeting 'significant' need
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised